Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Fineline Cube May 12, 2026
Company Drug

CanSino Biologics’ Five-Component Pertussis Vaccine Enters NMPA Priority Review for Ages 6+

Fineline Cube May 12, 2026
Company

CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases

Fineline Cube Sep 18, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first...

Company Deals R&D

GemPharmatech Partners with Daxiang Biotech to Advance Preclinical Evaluation Models

Fineline Cube Sep 18, 2023

Nanjing-based GemPharmatech Co., Ltd, a center for laboratory animal seed resources and a specialist in...

Company Drug

Akeso Biopharma’s AK132 Receives Green Light for Clinical Trial in Advanced Solid Tumors

Fineline Cube Sep 18, 2023

Akeso Biopharma’s (HKG: 9926) AK132, a bispecific antibody (BsAb) targeting Claudin18.2 and CD47, has received...

Company Medical Device

AcornMed Receives FDA Breakthrough Device Designation for Urothelial Carcinoma Liquid Biopsy

Fineline Cube Sep 18, 2023

Beijing-based tumor precision medicine specialist, AcornMed, has been granted Breakthrough Device Designation (BDD) by the...

Company Deals Digital

Baidu Health Partners with HOB Biotech to Innovate Allergy Detection and Treatment

Fineline Cube Sep 18, 2023

Baidu Health has entered into a strategic partnership with HOB Biotech Group, a leading in...

Company Medical Device

Tuodao Medical’s Percutaneous Puncture Surgery Robot NP100 Approved in China

Fineline Cube Sep 18, 2023

China-based surgical robot developer Tuodao Medical Technology Co., Ltd has received marketing approval for its...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for Irinotecan Liposome Injection

Fineline Cube Sep 18, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received market approval...

Company Medical Device

Jenscare Scientific’s Tricuspid Valve Replacement System Joins FDA’s TAP Program

Fineline Cube Sep 18, 2023

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that...

Legal / IP

Jiangsu Hengrui Pharmaceuticals Entangled in Legal Disputes with BeyondSpring and Reistone

Fineline Cube Sep 18, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is currently entangled in legal challenges involving...

Company

Astellas Pharma Invests EUR 330 Million in State-of-the-Art Manufacturing Plant in Ireland

Fineline Cube Sep 15, 2023

Japanese pharmaceutical company Astellas Pharma (TYO: 4503) has announced a significant investment of EUR 330...

Company Policy / Regulatory

China Launches Fourth National Volume-Based Procurement Tender Focusing on Medical Consumables

Fineline Cube Sep 15, 2023

The national high-value medical consumables joint procurement office has released a notification, marking the commencement...

Company

J&J Rebrands Pharmaceutical and MedTech Segments Post-Kenvue Separation

Fineline Cube Sep 15, 2023

Following the completion of its consumer healthcare unit separation as Kenvue (NYSE: KVUE) last month,...

Company Drug

Japan’s MHLW Reviews GSK’s Momelotinib for Myelofibrosis Treatment

Fineline Cube Sep 15, 2023

The Ministry of Health, Labour and Welfare (MHLW) in Japan has accepted for review a...

Company Drug

AstraZeneca and Daiichi Sankyo Report Positive Results for Datopotamab Deruxtecan Combo in NSCLC

Fineline Cube Sep 15, 2023

UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced positive data from a Phase Ib...

Company Deals

Sichuan Kelun Pharmaceutical Secures Exclusive Rights to TBM-001 for Bone Metastasis Diagnosis

Fineline Cube Sep 15, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...

Company Deals

Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery

Fineline Cube Sep 15, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...

Company Drug

Chongqing Lummy Pharmaceutical’s Subsidiary Receives NMPA Approval for CUD002 mRNA Vaccine

Fineline Cube Sep 15, 2023

Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006), through its subsidiary Sichuan Cunde Therapeutics Co., Ltd,...

Company Deals

Dialaibo Biotechnology Secures Series A Funding to Boost R&D and Manufacturing

Fineline Cube Sep 15, 2023

China-based Dialaibo (Zhangjiagang) Biotechnology Co., Ltd has reportedly raised close to RMB 100 million (USD...

Company R&D

Jiangsu Aidea Pharmaceutical Partners with National Medical Center for Infectious Disease on HIV Drug Development

Fineline Cube Sep 15, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...

Company Drug

Dizal Pharmaceutical’s Golidocitinib NDA Accepted for Review by NMPA

Fineline Cube Sep 15, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that the National Medical Products Administration...

Posts pagination

1 … 469 470 471 … 663

Recent updates

  • AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions
  • CanSino Biologics’ Five-Component Pertussis Vaccine Enters NMPA Priority Review for Ages 6+
  • GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market
  • Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms
  • Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Company Drug

CanSino Biologics’ Five-Component Pertussis Vaccine Enters NMPA Priority Review for Ages 6+

Others

GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.